On November 11 at 12 noon, the Florida Hospital Collaborative will be hosting a webinar entitled "Improving Outcomes for AV Fistulas."
Fistula First Breakthrough Initiative (FFBI) clinical consultants, Dr. Jay Wish of the University Hospital Case Medical Center in Cleveland, Ohio, and Dr. Michael Lilly of the University of Maryland, Baltimore, Maryland, will be the featured speakers. Included will be a discussion on the recently released FFBI Strategic Plan.
Please gather your questions and comments to create a lively discussion in this open question-and-answer forum.
The Top 10 Things Pharmacists Would Like to
Emphasize About ACE Inhibitor and ARB Use
According to an article recently released by FMQAI, "compelling indications for angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) use in hypertension include diabetes, chronic kidney disease (CKD), heart failure, recurrent stroke prevention, post-myocardial infarction and high coronary disease risk."
The article provides information on dosing, adverse effects, and combination therapy. To read the article, click here.
On the Forefront: End of Life Issues for Seniors
According to an article in NephrOnline, "'older Americans living in nursing homes experience a significant decline in their ability to perform simple daily tasks such as feeding themselves, getting dressed or brushing their teeth after starting dialysis,' say researchers at the Stanford University School of Medicine."
New Hemodialysis Access Device For Catheter-Dependent Patients
According to an article published in July 2009 in the Journal of Vascular Surgery, "The effects of a new long-term subcutaneous vascular access device were studied in access-challenged patients who were poor candidates for fistulas or grafts due to venous obstruction. Bacteremia rates, patency, and function of the Hemodialysis Reliable Outflow (HeRO) Vascular Access Device (Hemosphere Inc, Minneapolis, Minn) were evaluated."
The Medicare Quality Improvement Organization for Florida
FMQAI serves as the Medicare Quality Improvement Organization and End Stage Renal Disease Network (ESRD Network 7) for Florida. With a strong reputation as a leader in facilitating change and collaboration, FMQAI implements projects and conducts case review activities to improve care across all settings, including dialysis and transplant facilities.
This material was prepared by FMQAI, the Medicare Quality Improvement Organization (QIO) for Florida, under contract with the Centers for Medicare & Medicaid Services (CMS), an agency of the U.S. Department of Health and Human Services.The contents presented do not necessarily reflect CMS Policy.FL2009F73T1C1511486www.fmqai.com
FMQAI serves as the Medicare Quality Improvement Organization